6 results match your criteria mds-u poor

  • Page 1 of 1

[Analysis of Cytogenetic Characteristics and Clinical Prognosis in 236 Patients with Myelodysplastic Syndrome].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Aug;27(4):1190-1195

Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province,

Objective: To investigate the relationship of cytogenetic features, clinical characteristics and prognosis in patients with myelodysplastic syndrome.

Methods: The clinical characteristics and prognosis of 236 patients with MDS admitted to the Affiliated Hospital of Xuzhou Medical University from January 2013 to September 2017 were analyzed retrospectively, the follow-up observation and correlation analysis were performed.

Results: There were 33 cases of refractory cytopenia with unilateral dysplasia (RCUD), 8 cases of refractory anemia with ring-shaped iron granulocytes (RARS), 70 cases of refractory cytopenia with multiple dysplasia (RCMD), 23 cases of refractory anemia (RA), 46 cases of refractory anemia with excessive blasts (RAEB-1), 48 cases of (RAEB-2), MDS-U 2 cases, simple del(5q) 6 cases. Read More

View Article and Full-Text PDF

[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing].

Zhonghua Xue Ye Xue Za Zhi 2017 Dec;38(12):1012-1016

Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

To study the characteristics of gene mutations in Chinese myelodysplastic syndromes (MDS) patients. A total of 511 Chinese patients with MDS performed 112-gene targeted sequencing were retrospectively analyzed. Eighty-three distinct mutant genes were found in 511 patients with MDS. Read More

View Article and Full-Text PDF
December 2017

mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.

Biomark Res 2017 6;5:33. Epub 2017 Dec 6.

Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.

Myelodysplasia (MDS) /myeloproliferative neoplasm (MPN) overlap syndrome has been described since the 2001 WHO classification as disorders that have both proliferative and dysplastic changes simultaneously. Specific disorders include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), BCR-ABL negative atypical chronic myeloid leukemia (aCML) and unclassifiable MDS/MPN (MPN/MDS-U). Recurrent gene mutations in these conditions have been described. Read More

View Article and Full-Text PDF
December 2017

Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.

Am J Clin Pathol 2017 Jul;148(1):49-57

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY.

Objectives: Three situations qualify as myelodysplastic syndrome, unclassifiable (MDS-U): (1) refractory cytopenia with dysplasia and 1% blasts in peripheral blood (BL), (2) pancytopenia with unilineage dysplasia (Pan), and (3) persistent cytopenia, less than 5% bone marrow blasts, and less than 10% dysplastic cells and presence of MDS-defining cytogenetic abnormalities (CG). We compared the clinicopathologic features and mutational profiles for these three groups.

Methods: MDS-U cases were reviewed at four major academic institutions. Read More

View Article and Full-Text PDF

A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).

Am J Hematol 2017 Dec 28;92(12):1324-1332. Epub 2017 Sep 28.

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between April 2003 and March 2012 were collected from 20 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared with 115 non-hMDS patients. More RA and fewer CMMoL and RAEB-t in French-American-British (FAB) and more RCUD and MDS-U and fewer RCMD in World Health Organization (WHO) classifications were found in hMDS than non-hMDS with significant differences. Read More

View Article and Full-Text PDF
December 2017

[WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome].

Authors:
Xiao-Qin Wang

Zhonghua Nei Ke Za Zhi 2008 Jun;47(6):464-7

Hematology Department, Huashan Hospital, Fudan University, Shanghai 200040, China.

Objective: To investigate the WHO classification and cytogenetic characteristics of primary myelodysplastic syndrome (MDS) in adults of Shanghai area and then compare them with those of western countries.

Methods: The consecutive samples of 435 patients with MDS in Sino-US Shanghai Leukemia Cooperative Group were collected prospectively and diagnosed with WHO classification. Cytogenetic analysis was performed using chromosome G-banding and fluorescence in situ hybridization (FISH) techniques. Read More

View Article and Full-Text PDF
  • Page 1 of 1